Sold as Famvir. Every FDA application for this active ingredient: 1 branded and 8 generic.
As of Nov 16, 2026, FDA lists 9 applications for Famciclovir (sold as Famvir), first approved Jun 29, 1994, with 8 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Famciclovir | Part D | $6.4M | +1% | 56,331 |
| Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster PainHerpes Zoster Pain · Beijing Tiantan Hospital | Not applicable | Not yet recruiting | Jan 15, 2026 |
| Efficacy and Safety of Brivudine in the Treatment of Herpes ZosterHerpes Zoster · Peking University Third Hospital | Phase 4 | Recruiting | Aug 1, 2025 |
| Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster PainHerpes Zoster (HZ) · Xiaguang Duan | Not applicable | Not yet recruiting | Jan 29, 2025 |
| Effect of Mechanical Ventilation on Radiofrequency Ablation in Atrial FibrillationRadiofrequency Ablation, Atrial Fibrillation · Kocaeli City Hospital | — | Recruiting | Jan 24, 2025 |
| Jun 29, 1994 | FamvirNDA 20363 · New molecular entity | Novartis | 35 | Discontinued |
| Aug 24, 2007 | FamciclovirANDA 77487 | Teva Pharms | 5 | Marketed |
| Mar 21, 2011 | FamciclovirANDA 78278 | Cipla | 4 | Discontinued |
| Mar 21, 2011 | FamciclovirANDA 90128 | Hikma | 5 | Discontinued |
| Mar 21, 2011 | FamciclovirANDA 91114 | Aurobindo Pharma Ltd | 6 | Marketed |
| Mar 24, 2011 | FamciclovirANDA 201333 | Natco Pharma | 4 | Discontinued |
| Jul 22, 2011 | FamciclovirANDA 91480 | Apotex | 3 | Discontinued |
| Jan 12, 2012 | FamciclovirANDA 201022 | Macleods Pharms Ltd | 6 | Marketed |
| Sep 10, 2014 | FamciclovirANDA 202438 | Hetero Labs Ltd V | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA